Literature DB >> 6281389

Buprenorphine: high-affinity binding to dorsal spinal cord.

J W Villiger, K M Taylor.   

Abstract

The binding of the mixed opiate agonist-antagonist [3H]buprenorphine was compared with [3H]naloxone and [3H]dihydromorphine binding in membranes prepared from rat whole brain and dorsal spinal cord. Scatchard analysis of binding to whole brain yielded KD values close to 1.0 nM for all three 3H-ligands studied, although [3H]buprenorphine labelled five times as many binding sites. [3H]Naloxone and [3H]dihydromorphine bound to dorsal spinal cord with approximately the same affinity as to whole brain, although both 3H-ligands labelled fewer sites in the spinal cord. In contrast, Scatchard analysis of [3H]buprenorphine binding to spinal cord yielded curvilinear Scatchard plots, suggesting the presence of a very high-affinity (KD = 0.12 nM) binding site in addition to the high-affinity site (KD = 1.0 nM) present in the brain. Studies on the displacement of [3H]buprenorphine by opiates and D-Ala2,Met5-enkephalinamide supported the presence of two binding sites for this ligand in the spinal cord.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6281389     DOI: 10.1111/j.1471-4159.1982.tb06662.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  4 in total

1.  Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market.

Authors:  R Douglas Bruce; Sumathi Govindasamy; Laurie Sylla; Adeeba Kamarulzaman; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

2.  Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.

Authors:  Ashraf Yassen; Erik Olofsen; Eveline van Dorp; Elise Sarton; Luc Teppema; Meindert Danhof; Albert Dahan
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  On deriving the dose-effect relation of an unknown second component: an example using buprenorphine preclinical data.

Authors:  Ronald J Tallarida; Alan Cowan; Robert B Raffa
Journal:  Drug Alcohol Depend       Date:  2010-01-12       Impact factor: 4.492

4.  Clinical care of the HIV-infected drug user.

Authors:  R Douglas Bruce; Frederick L Altice
Journal:  Infect Dis Clin North Am       Date:  2007-03       Impact factor: 5.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.